Procedure : 2017/0024(NLE)
Document stages in plenary
Document selected : A8-0293/2017

Texts tabled :

A8-0293/2017

Debates :

Votes :

PV 24/10/2017 - 5.3

Texts adopted :

P8_TA(2017)0388

REPORT     *
PDF 620kWORD 94k
5.10.2017
PE 606.105v02-00 A8-0293/2017

on the proposal for a Council regulation amending the Council Regulation (EU) No 560/2014 of 6 May 2014 establishing the Bio-based Industries Joint Undertaking

(COM(2017)0068 – C8‑0118/2017 – 2017/0024(NLE))

Committee on Industry, Research and Energy

Rapporteur: Miroslav Poche

AMENDMENTS
DRAFT EUROPEAN PARLIAMENT LEGISLATIVE RESOLUTION
 EXPLANATORY STATEMENT
 OPINION of the Committee on Budgetary Control
 OPINION of the Committee on Regional Development
 PROCEDURE – COMMITTEE RESPONSIBLE
 FINAL VOTE BY ROLL CALL IN COMMITTEE RESPONSIBLE

DRAFT EUROPEAN PARLIAMENT LEGISLATIVE RESOLUTION

on the proposal for a Council regulation amending the Council Regulation (EU) No 560/2014 of 6 May 2014 establishing the Bio-based Industries Joint Undertaking

(COM(2017)0068 – C8‑0118/2017 – 2017/0024(NLE))

(Consultation)

The European Parliament,

–  having regard to the Commission proposal to the Council (COM(2017)0068),

–  having regard to Article 187 and the first paragraph of 188 of the Treaty on the Functioning of the European Union, pursuant to which the Council consulted Parliament (C8‑0118/2017),

–  having regard to Rule 78c of its Rules of Procedure,

–  having regard to the report of the Committee on Industry, Research and Energy and the opinions of the Committee on Budgetary Control and the Committee on Regional Development (A8-0293/2017),

1.  Approves the Commission proposal as amended;

2.  Calls on the Commission to alter its proposal accordingly, in accordance with Article 293(2) of the Treaty on the Functioning of the European Union;

3.  Calls on the Council to notify Parliament if it intends to depart from the text approved by Parliament;

4.  Asks the Council to consult Parliament again if it intends to substantially amend the Commission proposal;

5.  Instructs its President to forward its position to the Council and the Commission.

Amendment    1

Proposal for a regulation

Recital 1

Text proposed by the Commission

Amendment

(1)  Council Regulation (EU) 560/201437 established the Bio-based Industries Joint Undertaking (‘BBI Joint Undertaking’).

(1)  Council Regulation (EU) 560/201437 established the Bio-based Industries Joint Undertaking (‘BBI Joint Undertaking’) with the aim of contributing to the implementation of The Framework Programme for Research and Innovation (2014-2020) (‘Horizon 2020’) through increased investment in the development of a sustainable bio-based industry sector in Europe.

_________________

_________________

37 Council Regulation (EU) No 560/2014 of 6 May 2014 establishing the Bio-based Industries Joint Undertaking (OJ L 169, 7.6.2014, p. 130).

37 Council Regulation (EU) No 560/2014 of 6 May 2014 establishing the Bio-based Industries Joint Undertaking (OJ L 169, 7.6.2014, p. 130).

Amendment    2

Proposal for a regulation

Recital 2

Text proposed by the Commission

Amendment

(2)  Article 12(4) of the Statutes of the BBI Joint Undertaking, set out in the Annex to Regulation (EU) No 560/2014 ('the Statutes'), states that the financial contribution by the members of the BBI Joint Undertaking other than the Union to operational costs is to be at least EUR 182 500 000 over the period set out in Article 1 of Regulation (EU) No 560/2014, that is to say from the establishment of the BBI Joint Undertaking until 31 December 2024.

(2)  Article 12(4) of the Statutes of the BBI Joint Undertaking, set out in the Annex to Regulation (EU) No 560/2014 ('the Statutes'), states that the financial contribution by the members of the BBI Joint Undertaking other than the Union to operational costs is to be at least EUR 182 500 000 over the ten-year period set out in Article 1 of Regulation (EU) No 560/2014, that is to say from the establishment of the BBI Joint Undertaking until 31 December 2024.

Amendment    3

Proposal for a regulation

Recital 2 a (new)

Text proposed by the Commission

Amendment

 

(2a)  This Regulation responds to a proposal made by the Bio-based Industries Consortium Aisbl (BIC) and mirrors best practice in other joint undertakings. Effective programme delivery by the BBI Joint Undertaking and better regulation overall should continue to be achieved through improved cooperation, collaboration and engagement with all stakeholders, in particular small and medium-sized enterprises (SMEs) within the bio-based chain.

Amendment    4

Proposal for a regulation

Recital 3

Text proposed by the Commission

Amendment

(3)  The Bio-based Industries Consortium Aisbl (‘BIC’), which is a member of the BBI Joint Undertaking other than the Union, continues to be ready to support the operational costs of the BBI Joint Undertaking for the amount set out in Article 12(4) of the Statutes. It has however proposed an alternative mode of financing through financial contributions made by its constituent entities at the indirect actions' level.

(3)  The Bio-based Industries Consortium Aisbl (‘BIC’), which is a member of the BBI Joint Undertaking other than the Union, remains obliged, and continues to be ready, to support the operational costs of the BBI Joint Undertaking for the amount set out in Article 12(4) of the Statutes. It has however proposed an alternative mode of financing through financial contributions made by its constituent entities at the indirect actions' level.

Amendment    5

Proposal for a regulation

Recital 3 a (new)

Text proposed by the Commission

Amendment

(3a)  The alternative mode of financing proposed by the BIC has informed this Regulation, while recognising the unique features of the BBI Joint Undertaking. The Commission will examine how that alternative mode of financing could apply to other joint undertakings, and, in particular, to the Innovative Medicines Initiative Joint Undertaking.

Amendment    6

Proposal for a regulation

Recital 4

Text proposed by the Commission

Amendment

(4)  The objective of the BBI Initiative to carry out activities through collaboration of stakeholders along the entire bio-based value chains, including SMEs, research and technology centres and universities can be achieved only by enabling BIC and its constituent entities to deliver the financial contribution not only as payments to the BBI Joint Undertaking but also as financial contributions to indirect actions funded by the BBI Joint Undertaking.

(4)  The objective of the BBI Initiative to carry out, in line with the priorities of Horizon 2020, activities through collaboration of stakeholders along the entire bio-based value chains, including SMEs, research and technology centres and universities, and to make the Union a champion of research, demonstration, and deployment in the bio-based products and biofuels marketplace, can be achieved only by enabling BIC and its constituent entities to deliver the financial contribution not only as payments to the BBI Joint Undertaking. This new delivery mode is to ensure that the financial contributions become more commercially viable for BIC and its constituent entities, which in turn should facilitate the fulfilment of their financial obligations within the set deadline.

Amendment    7

Proposal for a regulation

Recital 4 a (new)

Text proposed by the Commission

Amendment

(4a)  In its joint undertaking process, the Commission set out the impact, effectiveness and lessons learnt from the proposed amendments. The Commission should submit a report to the European Parliament and to the Council assessing the effectiveness of this Regulation, in light of the BIC’s obligation to deliver its financial contribution by 31 December 2024.

Amendment    8

Proposal for a regulation

Recital 5 a (new)

Text proposed by the Commission

Amendment

 

(5 a)  In future cases the Commission should always carry out a public consultation in order to ensure that any proposed changes are accepted by all interested parties, and are developed in the most transparent and open manner possible. Similarly, the Commission should conduct impact assessments of the measures proposed unless the Better Regulation Guidelines clearly state otherwise.


EXPLANATORY STATEMENT

General context

Research and innovation are high risk activities and there is no guarantee of success. If the risk of failure is too large, the private sector may be unwilling to invest, even if the economic and societal returns could potentially be very large. In addition, the economic benefits of research investments may be captured by others, meaning that individual firms will be unwilling to invest. These general market failures provide a strong rationale for public support to private research and innovation activities. However, in a number of cases, the importance of the sectors, the complexity of the challenges and technologies, the long time periods involved and the scale of investment needed are such that public support to individual projects is not effective. It is for these cases that structured partnerships are needed between the public and the private sector to jointly develop, fund and implement ambitious research and innovation agendas.

For sectors that operate at European and international levels, and where the scale of the investments is beyond the means of individual Member States, the most effective approach is to establish such partnerships at EU level. For these reason Joint technology initiatives (JTIs) and Joint Undertaking (JUs) were set up as European institutional public-private partnerships to carry out the strategic research agenda of some established European technology platforms.

Six JTIs/JUs were already established under the 7th framework programme for research:

- Nanoelectronics technologies (ENIAC)

- Embedded computing systems (ARTEMIS)

- Innovative medicines (IMI)

- Aeronautics and air transport (CleanSky)

- Fuel cells and hydrogen (FCH)

- New generation European air traffic management system (SESAR)

Their legal framework was renewed under Horizon 2020 that led to a simplification of the rules and procedures. ENIAC and ARTEMIS were merged in a single Joint Undertaking on electronic components and systems: ECSEL and two more Joint Undertakings were created: Bio-based Industries Joint Undertaking (BBI JU) and Shift2Rail Joint Undertaking (S2R).

Seven Joint Undertakings are currently operational, receiving a €7.35 billion contribution from Horizon 2020.

Bio-based Industries Joint Undertaking

The BBI JU was set up by Regulation (EU) No 560/2014 and is due to operate for 10 years until 2024. The goal of the BBI JU is to bring all relevant stakeholders together and contribute to the advancement of Europe as a major research, demonstration, and deployment competitor in the bio-based products and biofuels marketplace. The budget of EUR 3705 million is divided between the EU (EUR 975 million, taken out of Horizon 2020: 800 million from Societal challenge 2 and 175 million from LEIT KET Biotechnology) and the Bio-based Industries Consortium (BIC) providing EUR 2730 million.

The rapporteur is persuaded that effective cooperation, for the purpose of research, between the public and private sectors is the key to delivering the best results for European citizens. Effective cooperation needs to be based on a well-functioning organisational and financial setup to ensure that all involved parties deliver on their commitments.

The first years of the BBI JU have shown that there is a need to implement certain modifications to the financial contribution management (the modality of delivering financial contributions) to operational costs. According to the present regulation, the private sector (represented by BIC) is expected to give financial contributions for operational costs directly to the BBI JU budget (i.e. financial contributions at a programme level). The BIC pointed out that this mechanism is commercially unviable for many companies. The present mechanism can leave companies´ contributions to go to the common budget while having no benefit from the projects being financed (from such contributions) by the BBI JU.

The financial contribution delivered by the BIC by the end of 2016 amounted to only € 0.75 million out of the total of € 182.5 million by the end of 2024 which proves the lack of viability of the present legal framework. Under art. 4(5) of the BBI JU Regulation, the low private financial contribution has led to a proportional suspension of the EU contribution, amounting to € 70 million for the moment. Therefore, the solution identified and agreed by all parties involved (European Commission and BIC) is to allow companies to deliver financial contributions also by making direct payments to other beneficiaries in the consortium (i.e. financial contributions at project level).

The Commission has positively reflected on the BIC remarks and suggests that contributions paid by members of BIC directly to individual projects should be permitted, too as part of the overall BBI JU scheme. Therefore amending the regulation only concerns Article 12 of the Statutes of the BBI JU (in the annex of the Council Regulation (EU) No 560/2014) where the forms of financial contributions are specified. The rapporteur is persuaded that it’s in the best interest of European research that Article 12 of the BBI JU Statutes is amended so the call for proposals for 2018 (planned to be published in early spring) can run under the new financial setup.

The rapporteur endorses the Commission’s proposal while emphasizing the following points:

-  the BIC obligation to deliver the financial contribution (EUR 182,5 million) as well as the level of accountability for complying with this obligation shall not be affected by the proposal

-  the current proposal does not affect the BIC financial contribution for administrative costs referenced in Article 12(2) of the BBI JU Statutes

-  relevant stakeholders, namely the national representatives in the States Representatives Group (SRG) and members of the academic community which are part of the Scientific Committee (SC), have been consulted on the current proposal and have expressed their favourable opinion on the proposed approach

-  all the calls for proposal will continue to be governed by the Horizon 2020 Rules

-  BBI JU will continue to provide its financial support to actions by means of open and transparent procedures, following open and competitive calls and will continue to select the proposals it will finance, following an impartial technical evaluation carried out by independent experts;

-  BBI JU will draft complementary guidelines following adoption of the amended regulation and a respective Model Grant Agreement will be modified accordingly.


OPINION of the Committee on Budgetary Control (5.9.2017)

for the Committee on Industry, Research and Energy

on the proposal for a Council regulation amending Council Regulation (EU) No 560/2014 of 6 May 2014 establishing the Bio-based Industries Joint Undertaking

(COM(2017)0068 – C8‑0118/2017 – 2017/0024(NLE))

Rapporteur: Luke Ming Flanagan

SHORT JUSTIFICATION

The Rapporteur and the committee believe that the modifications proposed by the Commission will allow greater flexibility of acquiring financial contributions from other sources than the EU budget. These modifications, already successfully in use in some of the other Joint Undertakings, ought to improve the multiplication effect resulting in more optimal use of taxpayers money. If these modifications will be adopted by the Council, the Budgetary Control Committee will be monitoring closely the effects of the change of financing rules on the performance of the JU during the next discharge procedures.

AMENDMENTS

The Committee on Budgetary Control calls on the Committee on Industry, Research and Energy, as the committee responsible, to take into account the following amendments:

Amendment    1

Proposal for a regulation

Recital 2 a (new)

Text proposed by the Commission

Amendment

(2a)  In accordance with a proposal made by the Bio-based Industries Consortium Aisbl (BIC), programme delivery by the BBI Joint Undertaking should be achieved through better collaboration with stakeholders, in particular small and medium-sized enterprises (SMEs) within the bio-based value chain.

Amendment    2

Proposal for a regulation

Recital 3 a (new)

Text proposed by the Commission

Amendment

(3a)  The alternative mode of financing proposed by the BIC has informed this Regulation, while recognising the unique features of the BBI Joint Undertaking. The Commission will examine how that alternative mode of financing could apply to other joint undertakings, and, in particular, to the Innovative Medicines Initiative Joint Undertaking.

Amendment    3

Proposal for a regulation

Recital 4 a (new)

Text proposed by the Commission

Amendment

(4a)  In its joint undertaking process, the Commission set out the impact, effectiveness and lessons learnt from the proposed amendments. The Commission should submit a report to the European Parliament and to the Council with regard to the effectiveness of this Regulation, in light of the BIC’s obligation to deliver its financial contribution by 31 December 2024.

Amendment    4

Proposal for a regulation

Recital 4 b (new)

Text proposed by the Commission

Amendment

(4b)  The Commission should conduct a cost-benefit analysis of the BBI Joint Undertaking’s remaining projects in light of the alternative mode of financing laid down in this Regulation.

Amendment    5

Proposal for a regulation

Recital 5

Text proposed by the Commission

Amendment

(5)  It is therefore necessary to amend the Statutes in order to enable BIC and its constituent entities to deliver the financial contribution for the full amount set out in Article 12(4) of the Statutes, allowing those contributions to be made not only as payments to the BBI Joint Undertaking but also as financial contributions to indirect actions funded by the BBI Joint Undertaking and to be reported to the BBI Joint Undertaking,

(5)  It is therefore necessary to amend the Statutes in order to enable BIC and its constituent entities to deliver the financial contribution for the full amount set out in Article 12(4) of the Statutes, allowing those contributions to be made not only as payments to the BBI Joint Undertaking but also as financial contributions to indirect actions funded by the BBI Joint Undertaking and to be reported to the BBI Joint Undertaking. A follow-up audit should, however, be conducted as soon as possible in order to ensure that the BIC continues to meet its commitments following implementation of this Regulation.

Amendment    6

Proposal for a regulation

Recital 5 a (new)

Text proposed by the Commission

Amendment

(5a)  In order to enhance the transparency of the procedure, it would be desirable for the Commission to carry out a wide consultation with the full participation of interested parties, as well as to draw up the requisite report on the impact of the proposed measures.

Justification

In order to ensure greater transparency, the Commission should carry out this consultation to verify that the proposed change has the support of interested parties.

PROCEDURE – COMMITTEE ASKED FOR OPINION

Title

Establishing the Bio-based Industries Joint Undertaking

References

COM(2017)0068 – C8-0118/2017 – 2017/0024(NLE)

Committee responsible

 

ITRE

 

 

 

 

Opinion by

       Date announced in plenary

CONT

15.6.2017

Rapporteur

       Date appointed

Luke Ming Flanagan

7.6.2017

Discussed in committee

12.7.2017

 

 

 

Date adopted

4.9.2017

 

 

 

Result of final vote

+:

–:

0:

17

4

0

Members present for the final vote

Jonathan Arnott, Inés Ayala Sender, Zigmantas Balčytis, Dennis de Jong, Tamás Deutsch, Martina Dlabajová, Raffaele Fitto, Luke Ming Flanagan, Ingeborg Gräßle, Cătălin Sorin Ivan, Jean-François Jalkh, Arndt Kohn, Claudia Schmidt, Bart Staes, Hannu Takkula, Indrek Tarand, Derek Vaughan, Joachim Zeller

Substitutes present for the final vote

Caterina Chinnici, Brian Hayes, Julia Pitera

FINAL VOTE BY ROLL CALL IN COMMITTEE ASKED FOR OPINION

17

+

ALDE

Martina Dlabajová, Hannu Takkula

GUE/NGL

Luke Ming Flanagan

EPP

Tamás Deutsch, Ingeborg Gräßle, Brian Hayes, Julia Pitera, Claudia Schmidt, Joachim Zeller

S&D

Inés Ayala Sender, Zigmantas Balčytis, Caterina Chinnici, Cătălin Sorin Ivan, Arndt Kohn, Derek Vaughan

Greens/EFA

Bart Staes, Indrek Tarand

4

-

ECR

Raffaele Fitto

EFDD

Jonathan Arnott

ENF

Jean-François Jalkh

GUE/NGL

Dennis de Jong

0

0

Key to symbols:

+  :  in favour

-  :  against

0  :  abstention


OPINION of the Committee on Regional Development (21.6.2017)

for the Committee on Industry, Research and Energy

on the proposal for a Council regulation amending Council Regulation (EU) No 560/2014 of 6 May 2014 establishing the Bio-based Industries Joint Undertaking

(COM(2017)0068 – C8‑0118/2017 – 2017/0024(NLE))

Rapporteur: Franc Bogovič

SHORT JUSTIFICATION

The Bio-based Industries Joint Undertaking (BBI) is a EUR 3.7 billion public-private partnership between the EU and the Bio-based Industries Consortium (BIC). It is dedicated to realising Europe’s bioeconomy potential by transforming renewable natural resources into bio-based products, materials and fuels by using innovative technologies and biorefineries.

The BBI was set up by Regulation (EU) No 560/2014, and is due to operate until 2024. Over that period, the Union’s financial contribution is EUR 975 million, and the private sector is to provide EUR 2 730 million in funding. The private sector funding is provided in two different ways: the major part of the funding is ‘in kind’, which does not flow through the budget of the BBI, whereas a smaller part is paid by industry to the BBI through the BIC.

Problems have arisen in this context, as certain businesses in the sector have difficulties in contributing to the BBI as a whole, but are willing to contribute to certain individual projects. In order to ensure that the promised contributions are actually received, the Commission therefore proposes that contributions paid by members of BIC directly to individual projects should be permitted as part of the overall BBI scheme.

It should be noted that this solution has already been adopted for the Innovative Medicines Initiative 2 Joint Undertaking.

The proposal merely seeks to amend two paragraphs in the BBI’s statute, which is annexed to Regulation (EU) No 560/2014. These minor amendments allow the operational costs of the joint undertaking to be covered also by direct contributions by industry, rather than only by contributions through the BIC and the BBI. The overall funding obligation for the private sector is not reduced.

Your rapporteur therefore proposes that Parliament should approve this modification. He also considers that the Committee on Regional Development should hold an exchange of views with the Commission on the upcoming review of the bioeconomy strategy prior to adoption, which is planned for November 2017, as well as on the bioeconomy manifesto prepared by the various stakeholders.

******

The Committee on Regional Development calls on the Committee on Industry, Research and Energy, as the committee responsible, to propose approval of the Commission proposal.

PROCEDURE – COMMITTEE ASKED FOR OPINION

Title

Establishing the Bio-based Industries Joint Undertaking

References

COM(2017)0068 – C8-0118/2017 – 2017/0024(NLE)

Committee responsible

 

ITRE

 

 

 

 

Opinion by

       Date announced in plenary

REGI

3.4.2017

Rapporteur

       Date appointed

Franc Bogovič

28.2.2017

Date adopted

20.6.2017

 

 

 

Result of final vote

+:

–:

0:

21

3

2

Members present for the final vote

Pascal Arimont, Franc Bogovič, James Carver, Rosa D’Amato, Ivan Jakovčić, Marc Joulaud, Constanze Krehl, Sławomir Kłosowski, Iskra Mihaylova, Konstantinos Papadakis, Stanislav Polčák, Liliana Rodrigues, Fernando Ruas, Monika Smolková, Ruža Tomašić, Ramón Luis Valcárcel Siso, Monika Vana, Matthijs van Miltenburg, Lambert van Nistelrooij, Kerstin Westphal

Substitutes present for the final vote

Elena Gentile, Arndt Kohn, Ivana Maletić, Bronis Ropė, Damiano Zoffoli

Substitutes under Rule 200(2) present for the final vote

Anna Hedh

FINAL VOTE BY ROLL CALL IN COMMITTEE ASKED FOR OPINION

21

+

ALDE

Ivan Jakovčić, Iskra Mihaylova, Matthijs van Miltenburg

ECR

Sławomir Kłosowski, Ruža Tomašić

PPE

Pascal Arimont, Franc Bogovič, Marc Joulaud, Ivana Maletić, Stanislav Polčák, Fernando Ruas, Ramón Luis Valcárcel Siso, Lambert van Nistelrooij

S&D

Elena Gentile, Anna Hedh, Arndt Kohn, Constanze Krehl, Liliana Rodrigues, Monika Smolková, Kerstin Westphal, Damiano Zoffoli

3

-

EFDD

James Carver, Rosa D'Amato

NI

Konstantinos Papadakis

2

0

Verts/ALE

Bronis Ropė, Monika Vana

Key to symbols:

+  :  in favour

-  :  against

0  :  abstention


PROCEDURE – COMMITTEE RESPONSIBLE

Title

Establishing the Bio-based Industries Joint Undertaking

References

COM(2017)0068 – C8-0118/2017 – 2017/0024(NLE)

Date of consultation / request for consent

21.3.2017

 

 

 

Committee responsible

       Date announced in plenary

ITRE

3.4.2017

 

 

 

Committees asked for opinions

       Date announced in plenary

CONT

15.6.2017

REGI

3.4.2017

 

 

Rapporteurs

       Date appointed

Miroslav Poche

17.5.2017

 

 

 

Discussed in committee

11.7.2017

 

 

 

Date adopted

2.10.2017

 

 

 

Result of final vote

+:

–:

0:

46

1

12

Members present for the final vote

Nikolay Barekov, Nicolas Bay, Bendt Bendtsen, Xabier Benito Ziluaga, José Blanco López, David Borrelli, Jonathan Bullock, Cristian-Silviu Buşoi, Edward Czesak, Jakop Dalunde, Pilar del Castillo Vera, Fredrick Federley, Adam Gierek, Theresa Griffin, Rebecca Harms, Hans-Olaf Henkel, Kaja Kallas, Barbara Kappel, Krišjānis Kariņš, Seán Kelly, Jaromír Kohlíček, Peter Kouroumbashev, Zdzisław Krasnodębski, Miapetra Kumpula-Natri, Janusz Lewandowski, Paloma López Bermejo, Edouard Martin, Angelika Mlinar, Csaba Molnár, Nadine Morano, Dan Nica, Aldo Patriciello, Miroslav Poche, Michel Reimon, Massimiliano Salini, Algirdas Saudargas, Sven Schulze, Neoklis Sylikiotis, Dario Tamburrano, Patrizia Toia, Evžen Tošenovský, Claude Turmes, Vladimir Urutchev, Kathleen Van Brempt, Henna Virkkunen, Martina Werner, Lieve Wierinck, Anna Záborská, Carlos Zorrinho

Substitutes present for the final vote

Pervenche Berès, Michał Boni, Rosa D’Amato, Jens Geier, Françoise Grossetête, Werner Langen, Olle Ludvigsson, Răzvan Popa, Dennis Radtke

Substitutes under Rule 200(2) present for the final vote

Claudia Schmidt

Date tabled

6.10.2017


FINAL VOTE BY ROLL CALL IN COMMITTEE RESPONSIBLE

46

+

ALDE

Angelika Mlinar, Fredrick Federley, Kaja Kallas, Lieve Wierinck

ECR

Edward Czesak, Evžen Tošenovský, Hans-Olaf Henkel, Nikolay Barekov, Zdzisław Krasnodębski

ENF

Barbara Kappel

PPE

Aldo Patriciello, Algirdas Saudargas, Anna Záborská, Bendt Bendtsen, Claudia Schmidt, Cristian-Silviu Buşoi, Dennis Radtke, Françoise Grossetête, Henna Virkkunen, Janusz Lewandowski, Krišjānis Kariņš, Michał Boni, Massimiliano Salini, Nadine Morano, Pilar del Castillo Vera, Seán Kelly, Sven Schulze, Vladimir Urutchev, Werner Langen

S&D

Adam Gierek, Carlos Zorrinho, Csaba Molnár, Dan Nica, Edouard Martin, Jens Geier, José Blanco López, Kathleen Van Brempt, Martina Werner, Miapetra Kumpula-Natri, Miroslav Poche, Olle Ludvigsson, Patrizia Toia, Pervenche Berès, Peter Kouroumbashev, Răzvan Popa, Theresa Griffin

1

-

EFDD

Jonathan Bullock

12

0

EFDD

Dario Tamburrano, David Borrelli, Rosa D'Amato

ENF

Nicolas Bay

GUE/NGL

Jaromír Kohlíček, Neoklis Sylikiotis, Paloma López Bermejo, Xabier Benito Ziluaga

VERTS/ALE

Claude Turmes, Jakop Dalunde, Michel Reimon, Rebecca Harms

Key to symbols:

+  :  in favour

-  :  against

0  :  abstention

Legal notice - Privacy policy